Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
← catalyst calendarNCT07363577 · readout ≤ 315 d
Sponsored by LB Pharmaceuticals Inc. (industry) · LBRX — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
456estimated
Sites
13
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-25 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Schizophrenia
Interventions
- Drug: LB-102 (50 mg tablet) — also filed as LB-102
- Drug: LB-102 (100 mg tablet) — also filed as LB-102
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline to Week 6 on the Positive and Negative Syndrome Scale
measured 6 weeks
Permalink · LBRX's whole pipeline · Catalyst calendar · Every registered study · What changed